Open AccessSynergistic inhibitory effects of low‑dose decitabine in combination with bortezomib in the AML cell line Kasumi‑1
Author(s) -
Vassiliki Mpakou,
Aris Spathis,
Anthi Bouhla,
Efthimia Mpazani,
Sotirios Papageorgiou,
Konstantinos Gkontopoulos,
Eirini Glezou,
Thomas Thomopoulos,
Periklis Foukas,
Vasiliki Pappa
Publication year - 2021
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2021.9628
Subject(s) - propidium iodide , cell cycle , decitabine , apoptosis , bortezomib , cancer research , viability assay , chemistry , population , microbiology and biotechnology , biology , programmed cell death , immunology , medicine , biochemistry , multiple myeloma , gene expression , environmental health , dna methylation , gene